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A B S T R A C T
Schizophrenia (SCZ) is a severe mental disorder with a high heritability. Although its pathophysiology is mainly
unknown, dysregulated immune activation and inflammation have recently emerged as possible candidates in
the underlying mechanisms of SCZ. Previous studies suggest that aberrant inflammasome activation, glia dys-
regulation, and brain inflammation may be involved in the pathophysiology of the disorder. Here, we studied the
effects of inflammatory modulation on human induced pluripotent stem cell (iPSC)-derived astrocytes generated
from SCZ patients and healthy controls (CTRL). Inflammasome activation was mimicked by short-term IL-1β
exposure, and gene expression were measured with high-coverage RNA-Seq to ensure a global characterization
of the transcriptional effects of the treatment. IL-1β exposure modulated several pathways involved in innate
immune responses, cell cycle regulation, and metabolism in both SCZ and CTRL astrocytes. Significant differ-
ences were found in the expression of HILPDA and CCL20 genes, both of which had reduced up-regulation upon
IL-1β treatment in SCZ astrocytes compared to CTRL astrocytes. CCL20 data were further validated and con-
firmed using qPCR, ELISA, and regulatory T lymphocyte (Treg) migration assays. Additionally, we found sig-
nificantly decreased mRNA expression of the Treg-specific marker FOXP3 in the blood of a large cohort of SCZ
patients (n = 484) compared to CTRL (n = 472). Since CCL20 is a specific chemoattractant for
CD4+CD25+CCR6+ Tregs, which are crucially involved in anti-inflammatory responses during brain (auto)in-
flammation, our results imply a plausible role for an altered astroglia-CCL20-CCR6-Treg axis in SCZ pathophy-
siology.
1. Introduction
Schizophrenia (SCZ) is a severe mental disorder that poses a con-
siderable burden on the affected individuals, with high impact on
morbidity and mortality, life quality, and costs of patient care world-
wide (Correll, 2015). Although it has high heritability, the details of its
patophysiology and etiology are still unknown. This gap of knowledge
hampers the treatment of patients as the identification of the under-
lying disease mechanisms in SCZ is essential for developing effective
new treatment regimens (Editorial, 2010; Rubinstein, 2010). Genome-
wide association studies (GWAS) have identified robust genetic asso-
ciations with SCZ in immune-related regions of the genome (DeLisi,
2002; Irish Schizophrenia Genomics Consortium and the Wellcome
Trust Case Control Consortium 2, 2012; Corvin and Morris, 2014;
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International Schizophrenia Consortium et al., 2009; Schizophrenia
Working Group of the Psychiatric Genomics Consortium, 2014). Dys-
regulated immune activation and inflammation could be involved in the
pathophysiology and represent an underlying mechanism explaining
different SCZ symptoms (Khandaker, 2015; Miyaoka, 2017). Indeed,
autoimmunity, infections, and CNS inflammation may play a role in the
manifestation of the disease (Bechter, 2010; Benros, 2011). Recent
studies suggest a role of neuroinflammation in SCZ as a result of dys-
regulated glia functions, and have linked endothelial cell activation and
systemic inflammatory markers to brain pathology (Najjar and
Pearlman, 2015; Dieset, 2015). Furthermore, elevated circulating levels
of inflammatory markers (e.g. interleukin [IL]-1 receptor antagonist
[IL-1Ra] and soluble tumor necrosis factor receptor type 1 [TNF-R1])
were shown to be associated with disease severity in SCZ, (Hope, 2013)
but the potential pathophysiological role of inflammation in SCZ is still
not clear.
Astroglia and microglia are resident immunocompetent cells of the
mammalian brain, (Heneka, 2018) and are potential candidates for
immune-abnormalities in SCZ (Khandaker, 2015). Recent studies in
astrocytes isolated from human postmortem samples and experimental
models indicate a plethora of changes in neuropsychiatric disorders.
These include decreased astrocyte cellular features and gene expression
in depression, chronic stress and anxiety, and, notably, increased in-
flammation in SCZ (Kim, 2018). Neuroinflammation may be a con-
sequence of dysregulated innate immune responses in the CNS against
various microbial, chemical, or physical insults evoked by exogenous or
endogenous danger signals. Inflammasomes, in particular NLRP3 in-
flammasomes, are an important part of innate immune responses where
activated caspase 1 cleaves the proforms of the inflammatory cytokines
IL-1β and IL-18 into their active and released forms (Heneka, 2018;
Singhal, 2014; Swanson et al., 2019). These cytokines play a critical
role in the activation of various down-stream inflammatory pathways,
and have also been suggested to be involved in psychiatric disorders,
such as SCZ, as a consequence of their dysregulated secretion by mi-
croglia and other brain-resident immune cells (Khandaker, 2015). Ele-
vated serum and postmortem brain IL-1β levels have been associated
with symptom severity and disease progression in SCZ (Zhu, 2018;
Mohammadi, 2018). Furthermore, abnormal inflammatory astrocyte
functions have recently been related to cognitive impairment and brain
volume reduction in SCZ (Kindler, et al., 2019).
There is, however, sparse direct evidence for immune pathology due
to the inaccessibility to human CNS tissue and the lack of appropriate
animal models of SCZ. Recent method developments in human iPSC
biology have enabled studies to elucidate cellular and molecular
anomalies in SCZ (Windrem, 2017; Falk, 2016). Direct reprogramming
of fibroblasts into iPSCs and their subsequent, controlled differentiation
to iPSC-neurons has been demonstrated to be a feasible model for in-
vestigating the molecular pathology of SCZ (Brennand, 2011; Tran,
2013). Here, we study the effects of inflammatory modulation on
human iPSC-derived astrocytes generated from SCZ patients and
healthy controls by using IL-1β as a prototypical and relevant in-
flammatory stimulus.
2. Materials and methods
2.1. Recruitment of patients and collection of skin biopsies
This project is part of the ongoing Norwegian TOP (Thematically
Organized Psychosis) study. Information about recruitment procedures,
inclusion and exclusion criteria, and clinical assessments for the TOP
study as a whole have been described in detail (Morch, 2019; Simonsen,
2011). For reprogramming and astrocyte differentiation, fibroblast/skin
biopsies were isolated from 3 CTRLs and 3 SCZ patients that were se-
lected based on clinical information. For gene expression measurements
of Treg markers in whole blood, a subset of the TOP sample consisting of
484 SCZ spectrum disorder patients (353 schizophrenia, 41 schizo-
phreniform, and 90 schizoaffective) and 472 CTRL subjects was used.
These participants were selected based on the availability of microarray
gene expression data for the relevant markers. A detailed description of
blood sampling procedures, microarray pre-processing, and quality
control can be found in a previous report (Akkouh, 2018). Tables 1 and
2 show further details about the study participants from whom skin
biopsies and whole blood samples were obtained, respectively. All pa-
tients underwent a clinical examination that included diagnostic in-
terviews based on Structured Clinical Interview in DSM-IV axis I Dis-
orders (SCID-1) and structured assessments of clinical symptoms, use of
psychotropic medication, smoking habits, alcohol consumption, and
illicit substance use. Diagnostic evaluation was performed by trained
clinical psychologists and psychiatrists. The main inclusion criteria
were confirmed diagnosis of SCZ according to the Diagnostic and Sta-
tistical manual of Mental Disorders (DSM)-IV, age between 18 and 65,
and ability to give informed written consent. The main exclusion cri-
teria were clinically significant brain injury, neurological disorder,
ongoing infections, autoimmune disorders or any form of cancer. All
participants have given written consent and the study was approved by
the Norwegian Scientific Ethical Committees and the Norwegian Data
Protection Agency. The project has been approved by the Regional
Ethics Committee of the South-Eastern Norway Regional Health Au-
thority (REK grant: #2012/2204 “Bruk av stamceller for å skaffe
kunnskap om sykdomsmekanismer ved alvorlige psykiske lidelser.”).
The authors assert that all procedures contributing to this work comply
with the ethical standards of relevant guidelines and regulations.
Table 1
Demographic characteristics of schizophrenia (SCZ) and healthy (CTRL) fibroblast donors participated in this study.
SCZ CTRL
donor 1 donor 2 donor 3 donor 1 donor 2 donor 3
Age at biopsy 23 27 20 33 38 46
Sex male female male female male female
Ethnicity Caucasian Caucasian Caucasian Caucasian Caucasian Caucasian
Table 2
Demographic and clinical characteristics of SCZ and CTRL subjects used for
gene expression measurements in whole blood.
SCZ (n = 484) CTRL (n = 472)
Mean SD Mean SD Test statistic p-value
Age 30.5 9.5 32.3 8.5 t = −3.10 1.99e-3*
Sex, female (n,
%)
189 39.0 209 44.3 χ2 = 0.84 0.36
Education
(years)
14.7 44.9 14.5 2.2 t = 0.13 0.89
*p < 0.05.
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2.2. Generation and maintenance of hiPSCs
Fibroblasts isolated from control and patient donors were grown
and expanded in vitro in DMEM containing 10% fetal bovine serum, 1%
penicillin/streptomycin, and 1% Glutamax. Cells were reprogrammed
using Sendai virus, transduced with the CytoTune™-iPS 2.0 Sendai
Reprogramming Kit (Thermo Fisher, Waltham, MA, USA) containing
KOS (Klf4, Oct4, Sox2), Nanog, and c-Myc reprogramming factors.
Virus vector was washed out after 24 h. At day 7 after transduction,
cells were plated on Vitronectin and medium was changed to Essential 8
Flex Medium (Thermo Fisher). Passaging of iPSC was done at a max-
imum of 80% confluency or every 3–4 days by using 0.5 mM EDTA for
3–5 min at 37 °C. Cells were split in 1:3 ratio on Geltrex coated plates in
the presence of 10 µM ROCK inhibitor Y27632 (Miltenyi Biotec,
Bergisch Gladbach, Germany). Complete elimination of virus was cor-
roborated in iPSCs at passage 10 by qPCR with specific SeV genome
detection primers (TaqMan Mr04269880-mr; Thermo Fisher). Each
iPSC line was subjected to rigorous quality control at The Norwegian
Center for Stem Cell Research including phenotyping, regular mon-
itoring of morphology, and pluripotency marker expressions.
Karyotyping examination of the chromosomal integrity of all the de-
rived iPSC lines was performed at passage 15 for verification of au-
thenticity and normality (KaryoStat Karyotyping Service, Thermo
Fisher). Karyotyping test results and hiPSC phenotyping data that are
not included in this paper are available upon request.
2.3. Differentiation of astrocytes from donor iPSCs
We differentiated astrocytes from patient and control iPSCs fol-
lowing previously published glial differentiation protocols with small
modifications (Izrael, 2007; Tcw, 2017). Briefly, iPSC colonies at pas-
sages 24–25 were transferred to 6-well tissue culture plates in Neural
maintenance medium (NMM) consisting of 50% DMEM/F12 and 50%
Neurobasal medium (both from Thermo Fisher) supplemented with
0.5% (v/v) N2, 1% (v/v) B27 (both from Invitrogen, Carlsbad, CA,
USA), 5 μg/ml human insulin, 40 ng/ml triiodothyronine (T3), 10 μM
β-mercaptoethanol, 1.5 mM L-glutamine, 100 μM NEAA, 100 U/ml
penicillin and 100 μg/ml streptomycin (all from Sigma-Aldrich, St.
Louis, MO, USA). 20 ng/ml EGF and 4 ng/ml bFGF (both from Pepro-
tech, Rocky Hill, NJ, USA) were added to the cultures. After 1 day, non-
adherent embryoid bodies (EBs) formed in the cultures and were fed
daily with NMM containing T3, EGF and bFGF (as above) until day 3
(Fig. 1B). On day 3, 10 μM all-trans retinoic acid (ATRA, Sigma) was
added to the medium and EBs were washed (1x, gently in NMM
medium) and plated on Geltrex-coated plates (Thermo Fisher). After
this step, cultures were fed with 10 μM ATRA + T3 + EGF + bFGF
supplemented NMM medium daily until day 10 (Fig. 1B). In order to
avoid the disruption of neurorosettes, cultures were not splitted until
day 10. On day 10, neurorosette formation was monitored by light
microscopy, and Nestin and PAX6 positivity was checked by qPCR.
Cultures were passaged using the cell dissociation agent Accutase
(Sigma) following the recommended protocol. From this point on,
regular passaging was done at confluence and cultures were seeded on
Geltrex-coated 6-well plates. On day 10, the medium was changed to
NMM + 40 ng/ml T3 + 20 ng/ml EGF. On day 18, after the formation
of neuroepithelium, the medium was changed to NMM supplemented
with B27 without vitamin A (Invitrogen) + 20 ng/ml EGF + 40 ng/ml
T3, and cultures were fed using the same medium composition until day
42. For astrocyte maturation and enrichment, medium was switched to
ScienCell AM medium (ScienCell, Carlsbad, CA, USA) on day 42, and
cells were further cultured for 60 additional days until day 102. Cul-
tures were continuously biobanked from day 42 by freezing astrocytes
in Sciencell AM medium + 10% DMSO at each passage, and storing
them in liquid nitrogen. Samples were continuously collected during
the differentiation process at days 0 (iPSC), 7, 14, 21, 30, and 40. The
mRNA expression of PAX6, Nestin, and the astrocyte-specific markers
GFAP, S100B, SLC1A2, SLC1A3, FABP7, AQP4, ALDH1L1, and ALDOC
was monitored by qPCR using a custom-made TLDA gene array card
(Thermo Fisher). Cells were stained with anti-GFAP, anti-MAP2 and
anti-NG2 antibodies (all from Abcam, Cambridge, UK) and were ana-
lyzed using fluorescent microscopy on day 42 (GFAP) and day 102
(GFAP, S100B, and AQP4, and GFAP, MAP2, NG2 co-staining). Astro-
cytes were considered mature and were used for experiments from day
102.
2.4. Inflammatory modulation of mature astrocytes
To mimic inflammasome activation in vitro, day 102 astrocytes were
treated with IL-1β at working concentrations of 0.1–10 ng/ml
(Peprotech). Cell pellets and culture supernatants were collected after
4 h of incubation for RNA-Seq and qPCR, and after 24 h of incubation
for ELISA and migration assay. Harvested samples were either im-
mediately used for analyses, or stored at −80 °C.
2.5. RNA extraction and sequencing
Total RNA was extracted from the differentiated astrocyte samples
using either the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany) or the
MagMax mirVana Total RNA Isolation Kit (Thermo Fisher) according to
manufacturer’s instructions. In both cases, approximately 1 million cells
were used as input. RNA yield was quantified with a NanoDrop 8000
Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA)
and RNA integrity was assessed with Bioanalyzer 2100 RNA 6000 Nano
Kit (Agilent Technologies, Santa Clara, CA, USA). All samples had an
RNA Integrity Number (RIN) > 8. Library preparation and paired-end
RNA-sequencing were carried out at the Norwegian High-Throughput
Sequencing Centre (www.sequencing.uio.no). Briefly, libraries were
prepared with the TruSeq Stranded mRNA kit from Illumina (San Diego,
CA, USA) which involves Poly-A purification to capture coding as well
as several non-coding RNAs. The prepared samples were then se-
quenced on a HiSeq 4000 sequencer (Illumina) at an average depth of
50 million reads per sample using a read length of 150 base pairs and an
insert size of 350 base pairs.
2.6. qPCR/TLDA array
cDNA was generated from 500 ng of total RNA, using the High-
Capacity cDNA Reverse Transcription Kit (Cat No. 4368813, Life
Technologies Corporation, Carlsbad, CA, USA) according to the manu-
facturer’s protocol.
qPCR was performed with custom designed TaqMan low density
array (TLDA) cards (Life Technologies; catalog numbers of the included
TaqMan probes are available upon request). Briefly, 100 ng of cDNA
was loaded per port according to the manufacturer’s protocol. The cards
were then cycled and analyzed on a Quantstudio 12 K Flex Real-Time
PCR system (Life Technologies), using the manufacturers standard
temperature profile. Using qBasePLUS software (v3.1), the delta-delta-
Cq model was used to determine relative target gene expression.
2.7. Data processing
Raw sequencing reads were quality assessed with FastQC
(Babraham Institute, Cambridge, UK). To pass the initial QC check, the
average Phred score of each base position across all reads had to be at
least 30. Reads were further processed by cutting individual low-quality
bases and removing adapter and other Illumina-specific sequences with
Trimmomatic V0.32 using default parameters (Bolger, 2014). Since the
trimming process may result in some reads being discarded and their
mates thereby unpaired, only reads that remained paired after trim-
ming were used for downstream analyses. HISAT2 (Kim, 2015) was
then used to first build a transcriptome index based on ENSEMBL an-
notations and then to map the trimmed reads to the human GRCh38
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reference transcriptome. To quantify gene expression levels, mapped
reads were summarized at the gene level using featureCounts (Liao,
2014) guided by ENSEMBL annotations.
2.8. Differential expression analysis
Before conducting the differential expression (DE) analyses, genes
with very low to zero expression were removed by filtering out any
gene with<1 read count per million (CPM) in more than 3 samples
(the smallest group sample size). DE analysis was performed using the
statistical R package DESeq2, which provides methods to test for dif-
ferentially expressed genes by use of negative binomial generalized
models (Love, 2014). We performed 3 different DE analyses to examine
the following: a) how cytokine treatment affects gene expression in
CTRL subjects, b) how cytokine treatment affects gene expression in
SCZ patients, and c) whether the effects of cytokine treatment on gene
expression are different across SCZ and CTRL groups. Donor-specific
variations were controlled for in all three experiments. In addition, to
take into account that individuals were nested within diagnostic groups
in the third analysis, the design formula was modified in accordance
with the recommendations provided in the DESeq2 vignette. The
DESeq2 workflow begins by taking raw read count data as input and
applies an internal normalization method that corrects for sequencing
depth and RNA composition. After the standard DE analysis which
consists of size factor estimation, dispersion estimation, and model
fitting, DESeq2 performs an independent filtering step that optimizes
the number of genes with adjusted p-values below a user-specified
significance level (0.05 in the present study) (Love, 2014). After the
pre-filtering and independent filtering steps, a total of 17,880 genes
were examined in the 3 DE analyses.
2.9. Pathway enrichment analysis
Pathway analysis of the nominally significant DE genes identified in
the third analysis was performed separately for the relatively up and
down-regulated genes using pathfindR with default parameters (Ulgen,
2018). Rather than treating all genes equally as many pathway analysis
tools do, pathfindR takes into account both the p-values and effect sizes
of individual genes. It also incorporates information on protein–protein
interactions between genes and thereby avoids the assumption that
each gene is independent from the other genes. The Kyoto Encyclopedia
of Genes and Genomes (KEGG) database (Kanehisa and Goto, 2000) was
used as the pathway reference database, except that we excluded all
pathway terms related to human diseases since we were primarily in-
terested in the molecular mechanisms and biological processes that the
identified DE genes are involved in.
2.10. Immunocytochemistry (ICC) and imaging
Samples were fixed with 4% paraformaldehyde for 10 min, and
washed 3 times with PBS for 15 min. Samples were blocked for 1 h with
10% normal horse serum (NHS; Abcam) in Tris-buffered saline con-
taining 0.5% (v/v) Triton X-100, pH 7.4 (TBSTx). Fixed cells were
further incubated overnight in 1% NHS in TBSTx with rabbit anti-GFAP
(diluted 1:500; Dako-Agilent) or goat anti-GFAP (diluted 1:500), rabbit
anti-S100B (1:400), rabbit anti-AQP4 (1:500), rabbit anti-MAP2 (di-
luted 1:400), mouse anti-NG2 (diluted 1:500), mouse anti-Oct4 or
rabbit anti-Nanog antibodies (all from Abcam). Samples were then
rinsed 3x with 1% NHS in TBSTx and and blocked again for one hour at
RT. Samples were incubated with secondary antibodies (1:500) for 2 h
at RT: Alexa Fluor 488 donkey anti-mouse IgG, Alexa Fluor 555 goat
anti-rabbit IgG, Alexa Fluor 647 donkey anti-goat IgG, Cy3 anti-rabbit
IgG, Cy2 anti-mouse (all from Abcam). The samples were then rinsed 3x
with 1% NHS in TBSTx and incubated for 5 min with the nuclear stain
Hoechst 33258 or DAPI (1 μg/ml in PBS; Sigma). The samples were
then rinsed for 10 min in PBS and mounted under coverslips in
PBS:glycerol 1:1. The samples were examined and imaged with a Zeiss
LSM 700 confocal microscope, or an Olympus AX70 fluorescent mi-
croscope. Images were processed using ImageJ software version 1.52p
(National Institutes of Health, USA). The number of GFAP-positive as-
trocytes was obtained by automated cell counting using an ImageJ
macro as previously described (Boulland, 2012).
Fig. 1. iPSC derivation and characterization. (A) Diagram of the main stages of the study. This figure was created using Servier Medical Art templates, which are
licensed under a Creative Commons Attribution 3.0 Unported License; https://smart.servier.com (B) Representative confocal microscopy images of iPSC lines (at
passage 15) derived from 3 SCZ patients and 3 CTRLs. Cells are staining positive for Oct4 and Nanog pluripotency markers. Scale bar: 100 μm. (C) An overview of the
applied protocol for astrocyte differentiation, activation, and analysis. For details, see Materials and Methods.
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2.11. ELISA assays
For sample preparation, 2.5 × 105 cells were cultured in 1 ml AM
medium in 12-well plate. Culture supernatants were harvested 24 h
after activation by 10 ng/ml IL-1β and the concentration of CCL20
chemokine was measured using MIP-3 alpha/CCL20 Human ELISA kit
(Thermo Fisher) following the manufacturer’s recommendations. For
HILPDA protein level measurements samples were prepared by lysing
2.5 × 105 cells following 24 h IL-1β treatment. Lysis of iPSC-astrocytes
was done using Pierce IP Lysis Buffer (Thermo Fisher) following the
recommended protocol. The protein level of HILPDA was assessed using
a human HILPDA/HIG2 ELISA kit (LSBio, Seattle, WA, USA). The pre-
cision of the ELISA kits were the following: Intra-Assay variation:
CV < 10%; Inter-Assay variation: CV < 12% (CV% = SD/
meanX100).
2.12. Isolation and phenotyping of regulatory T lymphocytes
Leukocyte-enriched buffy coats were obtained from anonymous
healthy blood donors drawn at the Oslo University Hospital Blood Bank
in accordance with the institutional guidelines. All enlisted donors were
healthy persons residing in Norway during the study period. Written
informed consent was obtained from the donors prior to blood dona-
tion, and their data were processed and stored according to the direc-
tives of the Norwegian Scientific Ethical Committees and the
Norwegian Data Protection Agency. Peripheral blood mononuclear cells
(PBMCs) were separated by a standard density gradient centrifugation
with Ficoll-Paque Plus (Amersham Biosciences, Uppsala, Sweden). Tregs
were isolated from PBMC by CD4-negative selection followed by CD25-
positive selection, using a CD4+CD25+ T cell isolation kit (Miltenyi).
After separation on a VarioMACS magnet, 95–98% of the cells were
CD4+CD25+ T cells as measured by flow cytometry (Supplementary
Table 1). Phenotyping of Tregs was performed by flow cytometry using
anti-CD4-FITC, anti-CD25-PE, and anti-CCR6-FITC (Abcam), and iso-
type-matched control antibodies (BD Pharmingen, San Jose, CA, USA).
Fluorescence intensities were measured by FACS Calibur (BD Bios-
ciences, Franklin Lakes, NJ), data were analyzed by the FlowJo soft-
ware (Tree Star, Ashland, OR).
2.13. In vitro transwell chemotaxis assay
The chemotaxis protocol was performed as described previously
(Zhang, 2009). Briefly, after isolation, CD4+CD25+ T cells were in-
cubated at 5% CO2 at 37C for 24 h before performing the chemotaxis
assay. Specific regulatory T cell migration was assessed by an 5 μm
Transwell system (Corning, Lowell, MA). A total of 5 × 105 CFSE la-
beled CD4+CD25+ Treg cells in RPMI 1640 containing 0.5% fatty acid-
free BSA (Sigma) were added in a volume of 100 μl to the upper wells of
a 24-well transwell plate with an 5 μm insert (Corning International,
Corning, NY, USA). 600 μl of AM medium (spontaneous migration ctrl),
or non-diluted supernatants from astrocyte cultures (24 h 10 ng/ml IL-
1β treated or non-treated, CTRL or SCZ) were added to the lower
compartment. The number of T lymphocytes that migrated to the lower
well following a 4-hour incubation step were counted under a fluor-
escent microscope using a hemocytometer.
2.14. CCR6 receptor neutralization
To block CCR6 receptor on CD4+CD25+ T lymphocytes, isolated
cells were treated with 10 µg/ml of anti-CCR6 polyclonal antibody
(extracellular domain-specific, Abgent, San Diego, CA, USA) or an IgG
isotype-matched control antibody (Biolegend, San Diego, CA, USA) for
1 h prior to migration assay set-up. Before assaying, cells were washed
two times using warm, sterile, serum-free RPMI medium and cen-
trifuged at 300 rpmi for 5 min to remove excess antibodies.
2.15. Glutamate uptake assay
Indirect assessment of glutamate uptake by resting iPSC-astrocytes
was done using a colorimetric glutamate assay kit following the man-
ufacturer’s recommendations (Abcam; Cat. no.: ab83389). Briefly, cells
were incubated in AM medium at 37 °C and 5% CO2 for 24 h then
supernatants were collected and assayed. Native AM cell medium
(medium control) and donor/clone-specific iPSC lines were used as
controls.
2.16. Statistics
In vitro T cell migration results represent mean values of triplicate
samples from SCZ and CTRL culture supernatants. All experiments were
performed three times using T cells from 3 independent healthy donors.
Data are presented as mean ± standard deviation. Comparisons be-
tween groups were done by independent sample t-tests or analysis of
variance (ANOVA) between groups. To test for significant differences in
the blood gene expression levels of Treg markers (CCR6 and FOXP3) in
SCZ patients compared to CTRLs, a multiple linear regression model
with adjustment for age and sex differences was performed in R 3.4.1.
3. Results
3.1. Generation and characterization of iPSC-astrocytes from SCZ and
CTRL subjects
3.1.1. Generation of iPSC-astroglia
To establish an in vitro human cellular model for evaluating the
effects of inflammatory modulation on iPSC-astroglia, we first repro-
grammed fibroblasts isolated from SCZ (n = 3) and CTRL donors
(n = 3) using Sendai virus vector (Fig. 1A; see Table 1 for a summary of
donor characteristics, and Materials and Methods for details on their
origin and derivation). On average, 3–5 clones were generated per
donor iPSC lines and were cultured for at least 5–10 passages to allow
time for the wash-out of virus before pluripotency testing. At passage
15, both control and patient iPSC lines stained positive for the plur-
ipotency markers Oct4 and Nanog (Fig. 1B), and robustly expressed the
Oct4, Nanog, and Sox2 genes (Fig. S1). One clone per donor was selected
for experiments and cultured for an additional 9–10 passages including
massive-scale cell banking in liquid nitrogen. Each in vitro experiment
was done in triplicates if not stated otherwise.
At passage 24–25 of the selected iPSCs, we derived astrocyte-like
cells using slightly modified versions of two previously published glial
differentiation protocols (Fig. 1C) (Izrael, 2007; Tcw, 2017). The ap-
plied retinoic acid (ATRA)-based neural induction conditions success-
fully generated cell populations with rosette-like structures derived
from embryiod bodies (EBs). Areas outside the neural rosettes exhibited
varying morphologies. To evaluate the different neural progenitor (NP)
populations for the expression of known markers and monitor the dif-
ferentiation of astrocytes from the earliest stages (day 0/iPSC), a
custom-made TLDA gene array was used to measure the expression of
the NP markers PAX6 (transcription factor regulating gene expression
during nervous system development) and Nestin (a type VI inter-
mediate filament protein expressed in multiplying cells of the devel-
oping nervous system), as well as of the key astrocyte markers GFAP
(Glial fibrillary acidic protein), S100B (S100 calcium-binding protein
B), AQP4 (Aquaporin 4), SLC1A2 and SLC1A3 (Solute Carrier Family 1
Member 2 and 3), and additional astroglia-specific markers: FABP7
(Fatty acid binding protein 7), ALDH1L1 (Aldehyde Dehydrogenase 1
Family Member L1), and ALDOC (Aldolase C).
3.1.2. Characterization of iPSC-astroglia
In general, all cultures in the neural rosette/NP stage highly ex-
pressed the critical markers PAX6 and NES, and these markers were
continuously expressed, although gradually downregulated throughout
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the differentiation process, in early astrocyte progenitors and fully
differentiated astrocytes (Fig. 2A and B), in agreement with the litera-
ture (Krejciova, 2017; Ho, 2017; Nadadhur, 2018). Astrocyte cultures
were successfully established from iPSC lines of both SCZ patients and
CTRLs. All lines exhibited the typical expression kinetics of developing
astroglia marker genes (GFAP; S100B, AQP4, SLC1A2, SLC1A3, FABP7,
and ALDH1L1 - Fig. 2C–I) (Molofsky and Deneen, 2015). Astroglial
markers that appear later in development (including GFAP, S100B,
SLC1A2, SLC1A3, and FABP7) showed robust mRNA expression only in
later stages (day 30 and 40 samples, Fig. 2C–G) corroborating a suc-
cessful differentiation trajectory of cell cultures (Molofsky and Deneen,
2015; Krencik, 2017). On day 40, AQP4 and ALDH1L1 gene expressions
increased only modestly (Fig. 2H and I), while ALDOC mRNA expres-
sion was not modulated significantly throughout the differentiation
process until this point (Fig. 2J) suggesting a skewing process towards
protoplasmic astroglial cellular identity in early iPSC-astrocytes
(Cahoy, 2008; Morel, 2017). No statistically significant differences were
observed between patients and controls in the gene expression pattern
of the astrocyte-specific markers at any time point up until day 40
(Fig. 2A–J). The astroglial phenotype of iPSC-derived cells was further
confirmed by ICC detection demonstrating expression of the key as-
trocyte marker GFAP in all iPSC-derived astrocyte cultures on day 42
(Fig. 2K).
After day 42, “young” astrocytes were cultured further for an ad-
ditional 60 days (~15–20 passages) in ScienCell AM medium that has
been previously shown to strongly promote and maintain iPSC-astro-
glial differentiation and maturation, as well as select for astrocytes in in
vitro cultures (Tcw, 2017). Our ICC results showed massive enrichment
(~99% purity) of astroglia, and robust expression of the astrocyte-
specific markers GFAP, S100B, and AQP4 in all iPSC-astrocyte cultures
on day 102 (Fig. 3A). Furthermore, no evident contamination by other
cell types, such as neurons or oligodendroglial progenitors could be
seen as tested by immunostaining with anti-MAP2 or anti-NG2 anti-
bodies, respectively (Supplementary Fig. S2). “Mature” astrocyte
phenotype was further confirmed by qPCR results showing the main-
tained gene expression of GFAP and FABP7 markers, and a strong in-
crease in the mRNA levels of S100B, ALDH1L1, AQP4, and SLC1A2
compared to “young” (day 42) astrocytes (Fig. 3B–G). We demonstrated
the functionality of mature astroglia by using a specific glutamate up-
take assay showing that CTRL and SCZ astroglia are capable of the
uptake process, but that non-astrocytic (iPSC) controls are not
(Fig. 3H). Both CTRL and SCZ iPSC-astrocytes demonstrated effective
uptake of glutamate relative to control (iPSC) cell cultures, and medium
control. No significant difference was observed between CTRL and SCZ
iPSC-astroglia in glutamate uptake (Fig. 3H).
3.2. Inflammatory modulation and comparative analysis of SCZ and CTRL-
derived iPSC-astrocytes
We next tested the effects of cytokine treatment on iPSC-astrocytes.
To mimic inflammasome activation, we applied physiologically re-
levant concentrations (0.1, 1, and 10 ng/ml) (Woiciechowsky, 1999;
Cacabelos, 1994) of IL-1β and investigated the short-term (4 h) effect
on early-response inflammatory cytokine genes using qPCR (Medzhitov,
2001). All applied concentrations of IL-1β strongly increased the ex-
pression of CXCL8/IL-8; IL6, and TNF genes in both SCZ and CTRL iPSC-
astrocytes, with no differences between patient and control lines (Fig.
S3). In general, the most pronounced effect was seen at an IL-1β con-
centration of 10 ng/ml (Fig. S3), and this concentration was therefore
used in subsequent experiments.
3.2.1. Unsupervised clustering
Principal Component Analysis (PCA) was used to cluster astrocyte
samples based on all expressed genes. We found a clear separation on
donor when clustering over the first two principal components (PCs),
explaining 64% of the variation in total (Fig. 4A). When clustering over
PC3 and PC4, we found a good separation on condition (IL-1β treated
vs. untreated) and diagnostic status (CTRL vs. SCZ), explaining 21% of
Fig. 2. iPSC-derived astrocyte differentiation and characterization. (A–J) Gene expression analysis of neural stem cell (PAX6, NES) and astrocyte-specific markers
(GFAP, S100B, SLC1A2, SLC1A3, FABP7, AQP4, ALDH1L1, ALDOC) in SCZ (black bars) and CTRL cultures (empty bars). Samples were collected during differentiation
from day 0 (iPSC) until day 40 and were analyzed using a custom-made TLDA gene array card (qPCR). Data of triplicate measurements of three independent donors
per group are presented as Mean ± SEM. K) Representative immunocytochemistry images of day 42 (“early”) astrocytes derived from 3 SCZ patients and 3 CTRLs.
Cells are stained positive for the specific astroglial marker GFAP. Scale bar: 150 μm.
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the variation in total (Fig. 4B). These results suggest that the donor
effect is an important source of gene expression variation that must be
accounted for when identifying the effects that are due to cytokine
treatment and diagnosis.
3.2.2. Differential expression analyses in CTRL and SCZ groups
We first performed two separate DE analyses investigating the gene
expression effects of IL-1β exposure in CTRL and SCZ samples, re-
spectively. In the CTRL group, the treatment significantly changed the
gene expression levels of 2213 genes (12.4%). Of these, 1358 genes
(61.4%) were up-regulated and 855 genes (38.6%) were down-regu-
lated (Fig. 4C; Supplementary Table S2). In the SCZ group, IL-1β
modulated the expression of only 779 genes (4.4%): 599 (76.9%) up-
regulated and 180 (23.1%) down-regulated (Fig. 4D; Supplementary
Table S3). The DE genes in both CTRL and SCZ groups had a similar
dynamic range of effect sizes (log2FCs from−2 to−10), and 647 genes
were shared by both groups (Fig. 4E). Moreover, the effect sizes of the
shared genes were highly correlated (r = 0.96; Fig. 4F). Most of the
genes affected by IL-1β stimulation were protein-coding (> 85%), but
also some miRNA and long non-coding RNAs were modulated
(Supplementary Tables S2-3). In general, genes involved in im-
munological functions were among the most affected, such as TNF,
CXCL11, and IL1B (Supplementary Tables S2-3).
3.2.3. Group-specific gene expression effects of cytokine treatment
To examine whether SCZ iPSC-astrocytes responded differently to
IL-1β exposure than CTRL astrocytes, we performed a group-specific
differential expression analysis. We found that 458 genes were modu-
lated differently across groups at the nominal significance level of
p < 0.05 (Fig. 5A, Supplementary Table 4). Of these genes, 255 were
relatively up-regulated, i.e. either more up-regulated or less down-
regulated in the SCZ group compared to the CTRL group, while 203
genes were relatively down-regulated, i.e. either less up-regulated or
more down-regulated in SCZ than in CTRL. Two genes remained sta-
tistically significant after multiple testing correction: CCL20
(p = 5.54e-6, logFC = −1.58) and HILPDA (p = 5.01e-6,
logFC =−1.06). For both of these genes, the up-regulatory effect of IL-
1β treatment was smaller in SCZ than in CTRL subjects (Fig. 5B). Se-
parate pathway analyses of the relatively up and down-regulated DE
genes suggested an enrichment for genes involved in cell cycle, signal
transduction, apoptotic, and neuronal processes (Fig. 5C,
Supplementary Table 5).
3.3. Reduced CCL20 secretion by SCZ astrocytes underlies decreased
migration of human Treg cells
Next, we sought to validate the HILPDA and CCL20 RNA-Seq results
using qPCR and ELISA assays. The qPCR analysis showed that IL-1β
treatment enhanced HILPDA and CCL20 mRNA expressions in CTRL
iPSC-astrocytes compared to SCZ cells, confirming the different stimu-
latory effect of IL-1β on the expression levels of these two genes as
revealed by RNA-Seq (Fig. 6A–C). Consistent with these results, SCZ
astrocytes secreted a significantly lower amount of the CCL20 cytokine
than CTRL iPSC-astroglia when culture supernatants were tested using
ELISA (Fig. 6D). Furthermore, we could not detect HILPDA protein in
iPSC-astrocytes neither at baseline nor after IL-1β treatment (high-
sensitivity ELISA, data not shown). To test the functional consequences
of reduced CCL20 secretion, we next investigated if IL-1β-activated
Fig. 3. Characterization of mature iPSC-derived astrocytes. (A) Cells from day 102 cultures stained positive for the key astrocyte markers GFAP, S100B, and AQP4.
Representative images from 3 donors with SCZ and 3 CTRLs are presented. Scale bar: 200 μm. (B-G) Gene expression screening of astroglia-specific markers in SCZ
(black bars) and healthy mature CTRL astrocyte cultures (empty bars). Samples were collected at days 0 (iPSC), 42 (early astrocyte), and 102 (mature astrocyte) and
analyzed using qPCR. Data of triplicate measurements of three independent donors per group are presented as Mean ± SEM. Asterisks represent statistically
significant differences between day 42/102 cells and day 0 (iPSC) cells at p < 0.05. (H) Glutamate uptake of resting iPSC-astrocytes was assessed using a glutamate
assay kit. Native AM cell medium (MC – “medium control”), and donor/clone-specific iPSC lines were used as controls (iPSC ctrl). Data of triplicate measurements of
three independent donors per group are presented as Mean ± SEM (in the case of MC, triplicate measurements were performed by sampling the same bottle of
medium in which all cells were cultured). Asterisks represent significant differences relative to iPSC controls at p values < 0.05; n.s. = ”non-significant”.
I.A. Akkouh, et al. Brain, Behavior, and Immunity 87 (2020) 634–644
640
astrocytes were capable of stimulating the migration of human
CD4+CD25+ Treg cells known to express the CCL20 chemoattractant-
specific chemokine receptor 6 (CCR6) (Kleinewietfeld, 2005). Our mi-
gration assay results showed that IL-1β-stimulated SCZ astrocytes
triggered a weaker migratory response compared to CTRL cells by at-
tracting significantly lower number of Treg cells in the assay setup
(Fig. 6E). Remarkably, this disparate chemoattracting effect on cell
migration between CTRL and SCZ was completely abrogated by
blocking the CCR6 receptor of Tregs, demonstrating the critical im-
portance of the CCR6-CCL20 axis in the observed phenomenon
(Fig. 6E).
3.4. Decreased expression of the Treg specific transcription factor FOXP3 in
SCZ patients
Since our findings suggested a possible link between defective as-
trocyte functions and regulatory T cell migration dynamics in SCZ, we
next investigated whether the two Treg-specific markers, CCR6 and
FOXP3, were differentially expressed in whole-blood samples from a
large cohort of SCZ patients (n = 484) and CTRLs (n = 472) (Fig. 7).
We found that SCZ patients had a slightly lower expression of FOXP3
that was statistically significant after controlling for age and sex
(p = 0.0137). No significant difference between patients and controls
was seen for CCR6 (Fig. 7). These results suggest a possible disease-
specific Treg cell defect in SCZ.
4. Discussion
In the present study, we explored the global transcriptomic effects of
IL-1β modulation on human iPSC-derived astrocytes generated from
SCZ and CTRL participants. We successfully established an in vitro iPSC-
astroglia model and found that inflammasome activation, as mimicked
by short-term IL-1β treatment, had a reduced up-regulatory effect on
CCL20 and HILPDA expression in SCZ. The effect on CCL20 was also
confirmed at protein levels, and importantly, IL-1β activated iPSC-de-
rived astrocytes had a weaker chemotactic effect on Treg cells. Our
blocking experiments suggested that this effect was mediated by as-
trocyte-derived CCL20. Based on the ability of Treg cells to control in-
flammation, our findings may suggest the attenuated CCL20 response
may contribute to a dysregulated brain inflammation in SCZ.
Understanding the mechanisms by which the immune system and
cytokines contribute to neuropsychiatric diseases could lead to the
identification of novel drug targets. According to recent findings, such
targets involve several inflammatory pathways including MAPKs, Nf-
kappaB, indoleamine-2,3-dioxygenase, and many others (Haroon,
2012). Previous studies have also showed altered expression of several
chemokines which again may influence the recruitment of various
lymphocyte subsets such as inflammatory Th1 and Th17 and anti-in-
flammatory Treg cells to the affected brain regions (McGlasson et al.,
2015). Brain inflammation due to dysregulated microglia functions and
inflammasome activation has been hypothesized to play an important
role in SCZ pathophysiology (Khandaker, 2015; Kim, 2016). Moreover,
IL-1β gene expression levels and polymorphism have also been asso-
ciated with SCZ symptom severity (Hänninen, 2008; Ghafelehbashi,
2017).
HILPDA (hypoxia-inducible lipid droplet-associated, also known as
HIG2) is an adipocyte-associated factor involved in lipid droplet for-
mation and metabolism, but also in IL-6 inflammatory trans-signaling
(Robinson, 2015; Jiang, 2015). Its biological function is not known yet,
but its expression is subject to strict translational/post-translational
control in many cell types, such as bone marrow-derived mesenchymal
stem cells, and the functional HILPDA protein is expressed only under
hypoxic stress (Jiang, 2015). Consistent with this, we found no de-
tectable levels of HILPDA protein in iPSC-astrocytes neither at baseline
nor after inflammatory stimulation, and the potential role of HILPDA in
SCZ should be further investigated using hypoxic experimental condi-
tions.
CCL20 is a chemokine that can be released by various cell types
Fig. 4. Effects of cytokine stimulation on global gene expression levels in iPSC-derived SCZ and CTRL astrocytes. A) PCA plot showing good separation on donor
across the first two PCs. B) When clustering across PC3 and PC4, a clear separation on treatment and diagnosis appears, explaining 21% of the gene expression
variance. C) The effect of cytokine treatment on gene expression in CTRL astrocytes. 1358 genes were significantly up-regulated and 855 were down-regulated, with
effect sizes ranging from log2FC −2 to 10. D) The effect of cytokine treatment on gene expression in SCZ astrocytes. 599 genes were significantly up-regulated and
180 were down-regulated. E) Overlap of significantly expressed genes in CTRL and SCZ astrocytes. F) Scatter plot showing the correlation of log2FCs for the 647
overlapping genes significantly regulated by cytokine treatment in both CTRL and SCZ samples. These genes were highly correlated in terms of both the direction and
magnitude of effect sizes. PC: Principal component, FC: Fold change.
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including astrocytes (Rothhammer and Quintana, 2015) and peripheral
blood mononuclear cells during inflammation, and is a highly specific
ligand for the non-promiscuous chemokine receptor CCR6 (Schutyser,
2003). The extreme selectivity of the CCR6/CCL20 ligand-receptor in-
teraction, in contrast to the binding characteristics of other chemokine
receptors, suggests a tightly regulated function (Schutyser, 2003). The
expression of CCR6 is restricted to only a few immune cell types in-
cluding a subset of IL-10 producing anti-inflammatory Tregs with high
migratory capacity towards tissue CCL20 signals (Kleinewietfeld, 2005;
Rivino, 2010; Cook, 2014; Liu, 2015). The physiological importance of
the CCL20-CCR6-Treg axis in regulating inflammatory processes in
many tissues has been noted by others (Kleinewietfeld, 2005; Rivino,
2010). Our results showed that IL-1β-treated SCZ iPSC-astrocytes se-
creted significantly lower amounts of CCL20 than CTRL cells, and the
functional consequence of this phenomenon was also demonstrated
using a T cell migration assay where SCZ astrocytes induced the mi-
gration of Tregs to a much lower degree than CTRL iPSC-astrocytes in a
CCL20-CCR6-dependent manner. Besides their role in regulating the
general neurophysiology of the brain, astrocytes also contribute to
neuroimmune homeostasis. Our finding thereby suggest that the
CCL20-mediated regulation of Treg chemotaxis, potentially also from
the blood to the brain, could be an important feature of astrocyte-
mediated immune regulation (Trajkovic, 2004; Ito, 2019). Dysregulated
inflammasome activation and the consequent release of IL-1β into the
brain parenchyma have been linked to a wide spectrum of neu-
ropsychiatric pathologies ranging from neurodegeneration (Heneka,
2018) to SCZ (Khandaker, 2015). Based on our results, we hypothesize
that a defective astroglia-CCL20-CCR6-Treg axis may represent a bio-
logical component of SCZ. We propose that a decreased number of anti-
inflammatory Tregs in the periphery and/or their reduced ingress to the
brain, due to the impaired ability of astrocytes to produce inflamma-
tion-modulating CCL20 molecules, fails to properly regulate CNS in-
flammation potentially contributing to the “inflammatory arm” in the
pathogenesis of of SCZ. This hypothesis is supported by recent clinical
findings showing increased numbers of circulating Tregs in SCZ patients
compared to the non-medicated SCZ group (Kelly, 2018). Further
support for this hypothesis can be found in our results showing lower
expression of the Treg-specific transcription factor FOXP3 in the whole
blood of SCZ patients relative to CTRLs, suggesting decreased number/
activity of Tregs in patients.
The field of psychiatry needs cellular and molecular biomarkers to
successfully address questions regarding the pathophysiological basis of
different mental disorders. Here we established a human in vitro iPSC-
based cellular model that presents astroglial features and phenotypes
both during differentiation and maturation. This model displays func-
tional immunocompetence by responding to IL-1β treatment via the
upregulation of early inflammatory response cytokine and chemokine
genes, as well as by secreting high levels of the CCR6+ Treg-attracting
chemokine CCL20. We identified defective IL-1β-induced CCL20 re-
sponses in SCZ astrocytes compared to controls resulting in impaired
chemotactic activity on Tregs as a major feature of iPSC-astrocytes in
SCZ patients. Our results support the “immunopsychiatric” or “glio-
pathy” hypothesis of SCZ, pointing to the possible involvement of as-
trocytes in the process. We propose that the astroglia-CCL20-CCR6-Treg
Fig. 5. Group-specific effects of cytokine treatment on global gene expression levels. A) Volcano plot showing cytokine-induced up and down-regulated genes in SCZ
astrocytes relative to CTRL astrocytes. With the exception of CCL20 and HILPDA, these genes were nominally significant at p < 0.05. B) Cytokine treatment resulted
in a reduced up-regulation of HILPDA and CCL20 in SCZ relative to CTRL. The effect remained significant after adjusting for multiple testing. C) Pathway analysis of
the nominally significant genes (including HILPDA and CCL20). Up-regulated genes showed strongest enrichment for molecular pathways related to cell cycle and
DNA replication, while down-regulated genes showed strongest enrichment for pathways involved in endocytosis and ribosome-related processes. CPM: Counts per
million.
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axis emerges as a promising candidate in future pharmacological stu-
dies in SCZ, and potentially also in other neuropsychiatric disorders.
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Fig. 6. Effects of IL-1β treatment in iPSC-derived astrocytes. (A-C) qPCR validation of HILPDA and CCL20 RNA-Seq expression data in SCZ astrocytes (black bars) and
healthy controls (empty bars) following IL-1β treatment. For HILPDA mRNA expression measurements both available Taq-Man probes (targeting two, partially
overlapping isoforms) were used (Fig. 6A and 6B). Data of triplicate measurements of three independent donors per group are presented as Mean ± SEM. Asterisk
means p values < 0.05. (D) Assessing CCL20 cytokine secretion in IL-1β-activated astrocyte cultures using ELISA. Mature astrocytes from 3 patients with SCZ (red
bars) or 3 CTRLs (blue bars) were treated with 10 ng/ml IL-1β for 24 h and supernatants were collected for cytokine measurements. Data of duplicate measurements
of three independent donors per group are presented as Mean ± SEM. (E) Effect of 10 ng/ml IL-1β-treated astrocyte culture supernatants on the migration of human
Treg cells. Migration assay was performed as described in Materials and Methods. Striped bars mean CTRL (blue) or SCZ (red) astrocyte supernatants modulating the
migration of Tregs following CCR6 receptor neutralization. White (CTRL) and black bars (SCZ) represent isotype control Ab setups. Data of duplicate measurements of
three independent donors in each group using pooled migration data of Treg cells isolated from 3 healthy donors are shown as Mean ± SD. Asterisk represents p
values < 0.05. (n.s. = “non-significant”). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 7. Expression of Treg-specific marker genes in whole blood of SCZ patients
and CTRL subjects. FOXP3 was slightly but significantly down-regulated in SCZ
patients compared to CTRL (p = 0.0137, β = −0.044). No significant differ-
ence in gene expression level was found for CCR6 (p = 0.697, β = −0.010).
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